Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.
Soumerai JD, Rosenthal A, Harkins S, Duffy J, Mecca C, Wang Y, Grewal RK, El-Jawahri AR, Liu H, Menard C, Dogan A, Yang L, Rimsza LM, Bantilan K, Martin H, Lei M, Mohr S, Kurilovich A, Kudryashova O, Postovalova E, Nardi V, Abramson JS, Chiarle R, Zelenetz AD, Louissaint A Jr. Soumerai JD, et al. Among authors: zelenetz ad. Blood. 2022 Oct 20;140(16):1822-1826. doi: 10.1182/blood.2022015443. Blood. 2022. PMID: 35802834 Free PMC article. No abstract available.
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, Noy A, Portlock CS, Straus DJ, Yahalom J, Nimer SD, Moskowitz CH. Hamlin PA, et al. Among authors: zelenetz ad. Blood. 2003 Sep 15;102(6):1989-96. doi: 10.1182/blood-2002-12-3837. Epub 2003 Apr 3. Blood. 2003. PMID: 12676776 Free article. Clinical Trial.
Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas.
Houldsworth J, Olshen AB, Cattoretti G, Donnelly GB, Teruya-Feldstein J, Qin J, Palanisamy N, Shen Y, Dyomina K, Petlakh M, Pan Q, Zelenetz AD, Dalla-Favera R, Chaganti RS. Houldsworth J, et al. Among authors: zelenetz ad. Blood. 2004 Mar 1;103(5):1862-8. doi: 10.1182/blood-2003-04-1359. Epub 2003 Nov 13. Blood. 2004. PMID: 14615382 Free article.
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz CH. Kewalramani T, et al. Among authors: zelenetz ad. Blood. 2004 May 15;103(10):3684-8. doi: 10.1182/blood-2003-11-3911. Epub 2004 Jan 22. Blood. 2004. PMID: 14739217 Free article. Clinical Trial.
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.
LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. LaCasce AS, et al. Among authors: zelenetz ad. Blood. 2012 Mar 1;119(9):2093-9. doi: 10.1182/blood-2011-07-369629. Epub 2012 Jan 10. Blood. 2012. PMID: 22234679 Free article.
Recent advances in the treatment of non-Hodgkin's lymphomas.
Abramson JS, Zelenetz AD. Abramson JS, et al. Among authors: zelenetz ad. J Natl Compr Canc Netw. 2013 May;11(5 Suppl):671-5. doi: 10.6004/jnccn.2013.0198. J Natl Compr Canc Netw. 2013. PMID: 23704240 Review.
312 results